^
Association details:
| Biomarker: | FGFR1 overexpression |
|---|---|
| Cancer: | Lung Cancer |
| Drug: | Iclusig (ponatinib) (Multi-tyrosine kinase inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Preselection of lung cancer cases using FGFR1 mRNA and gene copy number for treatment with ponatinib
Published date:
05/16/2018
Excerpt:
FGFR1 ISH (≥ 20% dot cluster [23% [29/126] cases]), associated with SCLC histology (p = 0.022), soft tissue metastases (p = 0.050) and shorter OS (p = 0.031). Four patients received ponatinib: All were FGFR1 ISH+….High FGFR1-mRNA is more common than FGFR1-AMP and was associated with worse OS.
DOI:
10.1200/JCO.2018.36.15_suppl.12095
Trial ID:
